Global Blood Therapeutics Garners $48,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f9da87a3-003d-437b-b158-8f5cc13d98a8
Date
1/6/2015
Company Name
Global Blood Therapeutics
Mailing Address
400 East Jamie Court South San Francisco, CA 94080 USA
Company Description
Global Blood Therapeutics, Inc. is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options.
Website
http://www.globalbloodtx.com
Transaction Type
Venture Equity
Transaction Amount
$48,000,000
Transaction Round
Series B
Proceeds Purposes
Proceeds from the financing will be used to advance the company’s lead drug candidate, GBT440, for the treatment of sickle cell disease (SCD). GBT440 has shown promising results in preclinical testing and the company is initiating a Phase I/II clinical trial.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor